[NH2:1][C:2]1[CH:10]=[CH:9][CH:8]=[C:7]2[C:3]=1[CH:4]=[N:5][N:6]2[C:11]([O:13][CH3:14])=[O:12].[C:15](Cl)(Cl)=[O:16].[CH:19]12[N:26]([C:27]3[CH:34]=[CH:33][C:30]([CH2:31][NH2:32])=[CH:29][C:28]=3[C:35]([F:38])([F:37])[F:36])[CH:23]([CH2:24][CH2:25]1)[CH2:22][CH2:21][CH2:20]2>C1(C)C=CC=CC=1.C1COCC1>[CH:23]12[N:26]([C:27]3[CH:34]=[CH:33][C:30]([CH2:31][NH:32][C:15]([NH:1][C:2]4[CH:10]=[CH:9][CH:8]=[C:7]5[C:3]=4[CH:4]=[N:5][N:6]5[C:11]([O:13][CH3:14])=[O:12])=[O:16])=[CH:29][C:28]=3[C:35]([F:38])([F:36])[F:37])[CH:19]([CH2:25][CH2:24]1)[CH2:20][CH2:21][CH2:22]2Methyl 4-amino-1H-indazole-1-carboxylate (1.72 g, 9.00 mmol) in toluene (300 mL) was treated with phosgene in toluene (9.00 mL, approx. 20% w/w) via syringe. The mixture was heated at reflux for 3.5 hours, allowed to cool to ambient temperature, and concentrated under reduced pressure. The residue was taken up in diethyl ether and concentrated under reduced pressure. The residue was again taken up in diethyl ether (325 mL) followed by addition of triethylamine (10 mL). The mixture was stirred briefly and then filtered. An aliquot of the filtrate (150 mL, 4.14 mmol) was treated with 4-(8-azabicyclo[3.2.1]oct-8-yl)-3-(trifluoromethyl)benzylamine (1.03 g, 3.62 mmol) in THF (10 mL). After stirring for 2 hours, the mixture was concentrated under reduced pressure to approximately 30 mL and filtered. The filter cake was washed with diethyl ether:hexane (1:1) and dried under reduced pressure to provide the title compound. 1H NMR (300 MHz, DMSO-d6) δ 9.07 (s, 1H), 8.43 (s, 1H), 7.80 (d, 1H, J=7.8 Hz), 7.69 (d, 1H, J=8.1 Hz), 7.58 (t, 1H, J=2.0 Hz), 7.47 (m, 2H), 7.14 (d, 1H, J=8.1 Hz), 6.86 (t, 1H, J=5.8 Hz), 4.32 (d, 2H, J=5.8 Hz), 4.03 (s, 3H), 3.72 (m, 2H), 1.93 (m, 2H), 1.88-1.55 (m, 5H), 1.49 (m, 3H); MS (ESI) 502 (M+H)+.